COCM
PMCB icon

Charter Oak Capital Management’s PharmaCyte Biotech PMCB Stock Holding History

Charter Oak Capital Management’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed – – 909
2021
Q3 		$0 Buy
+20
New +$70 ﹤0.01% 866

Other funds holding PMCB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Charter Oak Capital Management's PMCB Position: Q4 2021 in Review

Charter Oak Capital Management sold out of PharmaCyte Biotech (PMCB) in Q4 2021, closing a stake of 20 shares.

Charter Oak Capital Management first reported a position in PMCB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 26 funds tracked by Wall St. Rank hold PMCB as of Q4 2021.

  • Charter Oak Capital Management reported no remaining PharmaCyte Biotech position as of Q4 2021 after selling out during the quarter.
  • Charter Oak Capital Management sold 20 PharmaCyte Biotech shares in Q4 2021.
  • Charter Oak Capital Management first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 1 quarter.
  • Charter Oak Capital Management's PharmaCyte Biotech position peaked at $0 in Q3 2021.
  • 26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2021.

Based on Charter Oak Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.